Volume 25, Issue 5 (December & January 2022)                   J Arak Uni Med Sci 2022, 25(5): 10-19 | Back to browse issues page


XML Persian Abstract Print


1- Department of Nephrology, Labbafinezhad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran , nooshindalili4@gmail.com
2- Department of Nephrology, Labbafinezhad Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3- Shahid Beheshti Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract:   (181 Views)
Introduction: Years after the first successful kidney transplant, there are still many questions about the best immunosuppression regimen for these patients. Various studies have shown that long-term use of calcineurin inhibitor drugs can be associated with chronic nephrotoxicity and lead to irreversible damage to the transplanted organ. Therefore, the goal is to use immunosuppressive drugs and reduce the dose of calcineurin inhibitors as much as possible without increasing the risk of transplant rejection. This study aims to compare renal function, the rate of viral infections, and the occurrence of rejection after kidney transplantation in patients on two different treatment regimens including everolimus plus a low dose of calcineurin inhibitor against the standard protocol of calcineurin inhibitor along with mycophenolic acid in 60 kidney transplanted patients.
Methods: This clinical trial was conducted at Labbafinejad Hospital in Tehran between 2018-2019 on 60 kidney transplant patients aged 18 to 65 years and for 12 months.
Results: In terms of kidney function status based on GFR, except for the first month (P=0.02), there was no significant difference between the two groups in any of the time periods (P>0.05). Also, there was no statistically significant difference between the two study groups in terms of hospitalization length after transplantation and re-hospitalization during the study (P>0.05). 
Conclusions: The results of this study showed that the everolimus regimen and low dose of calcineurin inhibitor can be used de novo in transplant patients without increasing the risk of rejection in them and at the same time it may be able to reduce the incidence of viral infections after transplantation.
 
Full-Text [PDF 809 kb]   (114 Downloads)    
Type of Study: Original Atricle | Subject: Orology
Received: 2022/10/3 | Accepted: 2023/09/21

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.